|
|
Post by straightly on Apr 8, 2016 23:59:55 GMT -5
Well, we did for this week.
|
|
|
|
Daily PPS
Apr 9, 2016 7:56:42 GMT -5
via mobile
Post by patten1962 on Apr 9, 2016 7:56:42 GMT -5
Question about May 20th. Some people on this board believe the sp will be manipulated because of all the open contracts on this date. Can any of you offer opinions on this? Thank you.
|
|
|
|
Post by peppy on Apr 9, 2016 9:49:08 GMT -5
Question about May 20th. Some people on this board believe the sp will be manipulated because of all the open contracts on this date. Can any of you offer opinions on this? Thank you. Max pain, you made me look. maximum-pain.com/stock/MNKD.aspx pep
|
|
|
|
Post by robsacher on Apr 9, 2016 11:32:46 GMT -5
Nah, I expect we "may" see it stay the same if there is no good news or bad news. Other outcomes are also likely. BTW, I hope George Rho and Robert Sacher are primed to issue their perspectives once the post-transition landscape emerges. Articles by people who think clearly and comprehensively about the challenges and opportunities facing our intrepid company help blow away the FUD cloud. THank you for the compliment. George did publish a short response article to a pro shorting piece recently. I very much agree with George in his analysis. I also left a comment there stating that I have been adding to my position based on my belief that Pfeffer's team will figure out a way to get the marketing of Afrezza on a positive track by the end of this year. I also still firmly believe that the early adopters have proven that Afrezza is a superior insulin. I too am waiting for a "post transitional landscape" to emerge and so is my interior sub conscious, I believe. For what its worth, I had a dream last night that I awoke to a MannKind press release stating that management had signed an agreement with the Chinese government to open Afrezza clinics throughout mainland China. I went to the the Yahoo financial board and saw that MNKD had opened at $32 per share. Nice dream…  |
|
|
|
Post by straightly on Apr 9, 2016 20:57:02 GMT -5
Nah, I expect we "may" see it stay the same if there is no good news or bad news. Other outcomes are also likely. BTW, I hope George Rho and Robert Sacher are primed to issue their perspectives once the post-transition landscape emerges. Articles by people who think clearly and comprehensively about the challenges and opportunities facing our intrepid company help blow away the FUD cloud. THank you for the compliment. George did publish a short response article to a pro shorting piece recently. I very much agree with George in his analysis. I also left a comment there stating that I have been adding to my position based on my belief that Pfeffer's team will figure out a way to get the marketing of Afrezza on a positive track by the end of this year. I also still firmly believe that the early adopters have proven that Afrezza is a superior insulin. I too am waiting for a "post transitional landscape" to emerge and so is my interior sub conscious, I believe. For what its worth, I had a dream last night that I awoke to a MannKind press release stating that management had signed an agreement with the Chinese government to open Afrezza clinics throughout mainland China. I went to the the Yahoo financial board and saw that MNKD had opened at $32 per share. Nice dream… Darn it. My GTC sell order was set at $31.6! Maybe I should increase the price. |
|
|
|
Post by tayl5 on Apr 9, 2016 21:56:40 GMT -5
Nah, I expect we "may" see it stay the same if there is no good news or bad news. Other outcomes are also likely. BTW, I hope George Rho and Robert Sacher are primed to issue their perspectives once the post-transition landscape emerges. Articles by people who think clearly and comprehensively about the challenges and opportunities facing our intrepid company help blow away the FUD cloud. THank you for the compliment. George did publish a short response article to a pro shorting piece recently. I very much agree with George in his analysis. I also left a comment there stating that I have been adding to my position based on my belief that Pfeffer's team will figure out a way to get the marketing of Afrezza on a positive track by the end of this year. I also still firmly believe that the early adopters have proven that Afrezza is a superior insulin. I too am waiting for a "post transitional landscape" to emerge and so is my interior sub conscious, I believe. For what its worth, I had a dream last night that I awoke to a MannKind press release stating that management had signed an agreement with the Chinese government to open Afrezza clinics throughout mainland China. I went to the the Yahoo financial board and saw that MNKD had opened at $32 per share. Nice dream… Could happen, Rob. It's certainly a better dream than the current nightmare. |
|
|
|
Post by matt on Apr 10, 2016 7:22:11 GMT -5
Question about May 20th. Some people on this board believe the sp will be manipulated because of all the open contracts on this date. Can any of you offer opinions on this? Thank you. Stock prices can be volatile and volumes can be unpredictable as expiration dates for derivative contracts approach. Without bogging the explanation down in the underlying calculus, there is a mathematical relationship between the prices of stocks, bonds, calls, and puts. The price relationships are fluid early in the life of an option, but as the exercise date approaches this fluidity disappears and the mathematical differences converge on zero for options that are at, or close to, the exercise price.
Practically this means that if there are a lot of options outstanding with exercise prices very different from where the stock is trading come May, it really won't matter very much. On the other hand, if there are a lot of open options with exercise prices close to the trading price then you may see a lot of atypical price and volume movement. I would not characterize this as manipulation; it is merely the market responding to differences between the value of security portfolios which should, mathematically speaking, have identical prices. The price of the underlying basket of securities will increase or decrease until the market value of the portfolios is equal. If the market did not adjust prices in this way a clever investor could sell the overpriced portfolio and buy the underpriced portfolio thereby making a profit without taking any risk but, alas, there is no such thing as a free lunch.
|
|
|
|
Post by mnholdem on Apr 10, 2016 11:21:19 GMT -5
[Clipped] For what its worth, I had a dream last night that I awoke to a MannKind press release stating that management had signed an agreement with the Chinese government to open Afrezza clinics throughout mainland China. I went to the the Yahoo financial board and saw that MNKD had opened at $32 per share. Nice dream… Could happen, Rob. It's certainly a better dream than the current nightmare. Last week I read a U.S. government agency report on how Japan has recently reorganized their DO's and drug approval process to expedite FDA-approved drugs. What I found that warrants further study is that if Japanese patients are included in the FDA trial - even if they are U.S. citizens - then the Japanese DO has the option to rule that no further trials are needed for Japanese approval. They have been working with the FDA to formulate a policy by which the FDA encourages drug companies to include Japanese patients in the trial population. Now, if it turns out that multiple Japanese were among the Afrezza trial patients, this could bode well for expediting approval of Afrezza in Japan. This particular excerpt caught my attention: "The guideline ICH E5, the ethnicity guideline, can also be qualified as one of the most influential guidelines of the past, few years in Japan. The aim of this guideline was to reduce duplication of clinical studies by setting up a process for evaluating the possibility of extrapolating clinical data from one regulatory area to another. "Overall, this guideline has been successful in reducing the necessity to reproduce clinical research programs in Japan for drugs that have already been approved in the West. The guideline describes in detail which drugs may be more easily “bridged” from one area to the other. Experience has proven that it is by closely negotiating with the DO (Drug Organization) that companies have the best chances of obtaining approval." Source: www.ncbi.nlm.nih.gov/pmc/articles/PMC3181698/Japan was mentioned as being among the first countries MannKind/Sanofi would target outside the U.S. Expedited approval by Japan may not be news as big as China, be would still be welcome news. |
|
|
|
Post by alethea on Apr 11, 2016 12:18:18 GMT -5
Nah, I expect we "may" see it stay the same if there is no good news or bad news. Other outcomes are also likely. BTW, I hope George Rho and Robert Sacher are primed to issue their perspectives once the post-transition landscape emerges. Articles by people who think clearly and comprehensively about the challenges and opportunities facing our intrepid company help blow away the FUD cloud. THank you for the compliment. George did publish a short response article to a pro shorting piece recently. I very much agree with George in his analysis. I also left a comment there stating that I have been adding to my position based on my belief that Pfeffer's team will figure out a way to get the marketing of Afrezza on a positive track by the end of this year. I also still firmly believe that the early adopters have proven that Afrezza is a superior insulin. I too am waiting for a "post transitional landscape" to emerge and so is my interior sub conscious, I believe. For what its worth, I had a dream last night that I awoke to a MannKind press release stating that management had signed an agreement with the Chinese government to open Afrezza clinics throughout mainland China. I went to the the Yahoo financial board and saw that MNKD had opened at $32 per share. Nice dream… For what it's worth (not much, I'll admit) but I too had a very realistic dream that MNKD had been sold for $47 per share. I was all happy and glowing for some time after waking up! This occurred a year or so ago. Hoping that I have some latent Edgar Cayce capabilities heretofore not discovered! |
|
|
|
Post by kc on Apr 11, 2016 12:30:17 GMT -5
Question about May 20th. Some people on this board believe the sp will be manipulated because of all the open contracts on this date. Can any of you offer opinions on this? Thank you. Nice that the Shareholders meeting is the day before. Makes for an exciting end to 20th date. |
|
|
|
Post by peppy on Apr 11, 2016 12:43:05 GMT -5
Question about May 20th. Some people on this board believe the sp will be manipulated because of all the open contracts on this date. Can any of you offer opinions on this? Thank you. Nice that the Shareholders meeting is the day before. Makes for an exciting end to 20th date. options expire that week as well. |
|
|
|
Post by coo2002coo on Apr 12, 2016 9:25:56 GMT -5
MA 20 = $1.70 has become a resistance point to break?
|
|
|
|
Post by myocat on Apr 12, 2016 9:57:21 GMT -5
Well, I missed my re-entry point at 1.20.
|
|
|
|
Daily PPS
Apr 13, 2016 22:28:00 GMT -5
via mobile
Post by patten1962 on Apr 13, 2016 22:28:00 GMT -5
People have to be thinking something good is coming on Tuesday. Stock should move up just on speculation alone!
|
|
|
|
Post by humann on Apr 14, 2016 18:14:12 GMT -5
any ideas on the AH price movement (up ~4%)?
|
|
